CoVista’s core model is highly defensible due to regulatory barriers, entrenched employer partnerships, and scale. Enrollment and revenue growth are broad-based and recurring, with no evidence of peak or saturation. Margins are expanding, cash flow is strong, and capital allocation is disciplined. …
CoVista (CVSA) Q4 2026: Enrollment Surges 14% at Walden, Setting Stage for Multi-Year Platform Expansion
CoVista closed fiscal 2026 with record enrollment momentum and outperformance across all segments, positioning the company to accelerate its “Purpose at Scale” strategy in 2027. Durable healthcare workforce demand and operational leverage drove margin expansion and robust cash generation, while new capacity, employer partnerships, and AI-enabled learning signal long-term growth levers. With secular tailwinds and a proven execution model, CoVista’s forward guide reflects confidence in sustaining profitable growth, even as investments in platform extension and technology intensify.
Summary
- Enrollment Acceleration: Walden’s double-digit growth and Chamberlain’s recovery signal broad-based demand strength.
- Capital Deployment: Free cash flow and repurchases support both expansion and shareholder returns.
- Strategic Leverage: Employer integration and AI investments underpin multi-year growth visibility.
Business Overview
CoVista is a leading provider of healthcare workforce education, operating across three main segments: Chamberlain (nursing education), Walden (online health and non-health programs), and MedVet (medical and veterinary education). The company generates revenue primarily from tuition and related educational services, with a business model focused on enrollment growth, program expansion, and platform efficiency. CoVista’s scale and regulatory standing enable it to serve over 100,000 enrolled students, addressing persistent healthcare staffing shortages nationwide.
Performance Analysis
CoVista delivered a robust Q4, with revenue growth led by Walden (up 15.7% YoY) and MedVet (up 10.7% YoY), while Chamberlain returned to positive total enrollment growth. Walden’s enrollment reached nearly 55,000 students, up 14% and marking its ninth consecutive quarter of double-digit growth. Chamberlain reported its second straight quarter of positive total enrollment, driven by pre-licensure nursing and pricing optimization. MedVet also accelerated, with enrollment up 7.3%.
Margin expansion was a highlight, as adjusted EBITDA margin rose 120 basis points in Q4 and 100 basis points for the year, reflecting operational leverage and disciplined cost control despite elevated investment in strategic initiatives. Free cash flow surged 39% YoY, enabling $238 million in share repurchases and a net leverage reduction to 0.5x, underscoring financial flexibility. Lower interest expense and share count further boosted EPS, offsetting a higher effective tax rate.
- Walden Enrollment Outperformance: Broad-based growth across all degree levels, with undergrad up over 20%, and continued compounding from student persistence initiatives.
- Chamberlain’s Sequential Recovery: Pre-licensure BSN momentum and stabilization in post-licensure portfolios drove total enrollment gains.
- MedVet Pipeline Strength: On-the-ground recruitment and tech-enabled admissions supported top-line and margin gains, despite some enrollment pull-forward due to loan changes.
Operational and financial momentum positions CoVista ahead of its long-term targets, with platform extension and technology investments poised to drive further upside in fiscal 2027.
Executive Commentary
"The results are worth stating plainly. On the operational side, we delivered 12 consecutive quarters of total enrollment growth across the company. Record enrollments at Walden and Chamberlain during fiscal 26, 100,000 enrolled students, up from 76,000, joining a community of 400,000 alumni, delivering care in nearly every community in the country. Those gains converted into revenue, margin, and free cash flow."
Steve Beard, Chairman and Chief Executive Officer
"Our results demonstrate the durability of the operating model we have built, sustained enrollment growth, expanding margins, robust cash generation, and a balance sheet that gives us significant flexibility as we begin our next chapter, purpose at scale."
Bob Thalen, Chief Financial Officer
Strategic Positioning
1. Platform Extension Drives Capacity and Reach
CoVista is aggressively expanding its campus footprint and program formats, particularly at Chamberlain, with six new campuses in development and three fully approved. New locations are capital-light, targeting EBITDA break-even within 24 months and accretive margins. Evening and weekend offerings and broader course access in urban markets are designed to boost persistence and tap new student segments without materially increasing fixed costs.
2. Employer Integration as a Differentiated Enrollment Engine
Strategic partnerships with major health systems, such as SSM and the newly announced Advocate Health collaboration, are embedding CoVista’s programs into employer talent pipelines. These partnerships lower student acquisition costs, increase persistence, and create a more predictable, durable enrollment model, while offering health systems a differentiated, ready-to-hire clinician pipeline.
3. Technology and AI-Enabled Learning
CoVista is investing in AI-powered classroom prototypes and credentialing partnerships (e.g., Google Cloud), with over 9,000 learners already enrolled in new AI certificate offerings. Early adaptation to AI-driven search and answer platforms positions the company to maintain top-of-funnel strength as prospective student behavior shifts, leveraging authoritative content and trusted brands to sustain conversion rates.
4. Operating Discipline and Capital Allocation
Margin expansion and free cash flow generation have enabled both reinvestment and aggressive share repurchases, with $662 million remaining on the current buyback authorization. Debt refinancing and a net leverage of 0.5x provide ample capacity to fund growth initiatives and absorb potential volatility from regulatory or macro headwinds.
5. Leadership and Governance for Next-Phase Growth
Recent board and executive additions bring deep experience in regulated markets, platform expansion, and performance acceleration, ensuring the organization is structurally prepared for the complexity and scale of its next growth phase.
Key Considerations
Fiscal 2026 marked the completion of CoVista’s “Growth with Purpose” strategy, with all major financial and operational targets exceeded. The company now enters its “Purpose at Scale” era, focused on leveraging its platform, employer relationships, and technology for multi-year growth.
Key Considerations:
- Enrollment Momentum Across Segments: Sustained double-digit growth at Walden and sequential improvement at Chamberlain and MedVet underpin revenue visibility.
- Employer Partnerships as a Moat: Deeper integration with leading health systems creates a recurring, lower-cost enrollment channel and enhances student outcomes.
- AI and Digital Transformation: Early investment in AI-powered learning and marketing adaptation to agentic search platforms is an emerging differentiator.
- Capital Flexibility: Strong cash flow and a conservative balance sheet enable simultaneous investment and capital return, reducing risk from external shocks.
- Regulatory and Macro Sensitivity: While demand is secular, ongoing vigilance is required as loan program changes and professional program definitions evolve.
Risks
Regulatory changes, such as shifts in loan eligibility or program definitions, remain a persistent risk, particularly for MedVet and Chamberlain. While management sees recent changes as net positive, any future tightening could impact enrollment cycles. Competition for clinical placements and the pace of healthcare wage inflation may pressure operating margins if not offset by pricing or efficiency gains. Finally, as AI-driven search platforms evolve, maintaining top-of-funnel brand visibility will require continued investment and agility.
Forward Outlook
For Q1 2027, CoVista expects:
- Accelerated total enrollment growth at Chamberlain, continuing sequential improvement from Q3 and Q4 2026.
- Growth at Walden and MedVet to moderate against tougher comps, with calendar shifts impacting quarterly phasing but not full-year totals.
For full-year 2027, management guided to:
- Revenue of $2.05 to $2.09 billion, up 5% to 7% YoY
- Adjusted EPS of $8.90 to $9.15, up 8% to 11% YoY
- 0 to 50 basis points of EBITDA margin expansion, with more improvement expected in the back half of the year
Management cited structural healthcare workforce demand, ongoing campus expansion, and digital innovation as key growth drivers, with capital allocation balanced between reinvestment and buybacks. Higher effective tax rates and first-half investment levels are expected, but full-year margin targets remain intact.
- Chamberlain’s enrollment trajectory and new campus ramp are central to 2027 upside.
- AI and employer partnerships are expected to compound over the next several cycles.
Takeaways
CoVista’s Q4 and full-year results reinforce its position as the leading healthcare education platform in the US, with secular demand, operational leverage, and innovation underpinning multi-year growth prospects.
- Enrollment Outperformance: Walden’s record growth and Chamberlain’s recovery validate the company’s model and set a high bar for 2027.
- Strategic Moats Widening: Employer integration and AI investments are embedding CoVista more deeply in the healthcare workforce pipeline, creating durable competitive advantages.
- Forward Focus: Investors should monitor campus ramp velocity, employer partnership scale, and the impact of AI on student acquisition as key levers for sustained upside.
Conclusion
CoVista exits fiscal 2026 with record enrollment, margin expansion, and a platform primed for scale. With secular healthcare staffing shortages and proven execution, the company’s multi-pronged growth strategy and capital flexibility position it to deliver durable shareholder value through 2027 and beyond.
Industry Read-Through
Healthcare education and workforce development remain a secular growth market, with demographic shifts and clinical staffing shortages driving persistent demand. CoVista’s results and strategic moves highlight the growing importance of employer-education partnerships, digital program flexibility, and AI-enabled student engagement, themes likely to shape the sector. Competitors without platform scale, regulatory standing, or digital agility may struggle to match enrollment momentum or margin resilience. The shift to AI-driven student acquisition and persistent regulatory scrutiny are industry-wide watchpoints, underscoring the need for operational discipline and continuous innovation across the education landscape.